SER150: Ph IIa ongoing

Serodus completed dosing of about 72 patients in a double-blind, placebo-controlled, German Phase IIa trial evaluating 15 and 30 mg oral SER150 twice daily for 28 days. Serodus has exclusive, worldwid...